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Introduction 
Whereas the majority of influential cardiolo- 
gists initially embraced the biotechnology 
achievement and TIM1 I superiority’ associated 
with tissue plasminogen activator (tPA), now the 
previously beleaguered streptokinase and 
APSAC advocates are gaining their measure of 
revenge after years of being intellectually sup- 
pressed by the tPA  advocate^.^-^ Early infarct 
artery patency at whatever cost (or expense) be- 
cause “time is muscle” is no longer supposed to 
be the driving hypothesis behind selecting a lytic 
agent because comparative trials have not dem- 
onstrated drug related differences in left ventricu- 
lar ejection fraction or m~r ta l i t y .~  Rather, sus- 
tained patency at 24 hours is being touted as more 
predictive of clinical outcome even as a major 
effort continues to investigate prehospital admin- 
istration of thrombolytic therapy in order to save 
precious minutes initiating therapy.6 As in any 
debate, both sides are selectively quoting data 
to support their respective arguments. So what 
patency rates are we really comparing and is early 
infarct artery patency the goal or not? 
A number of differences in study design influ- 
ence the determination of patency rates in reper- 
fusion reports. First, studies using clinical mark- 
ers of reperfusion including relief of chest pain, 
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normalization of ST segment elevation, or bursts 
of accelerated idioventricular rhythm have occa- 
sionally been included with angiographic studies, 
even though they do not accurately reflect pa- 
tency.’ Coronary angiography should be the only 
standard by which to evaluate reperfusion. Sec- 
ond, doses and infusion times of some thrombo- 
lytic agents have varied widely. Higher doses or 
more rapid infusion times have improved patency 
rates in studies with alteplase and longer infu- 
sions may have reduced reocclusion rates in other 
studies.’ Third, time to treatment is important be- 
cause organization of the thrombus begins to 
occur after the first few hours, decreasing acute 
patency rates in patients who present later for 
treatment.’ This appears more important when 
streptokinase or APSAC are used. Fourth, time 
to angiography influences results. Ninety-minute 
patency rates are “snapshots” in time, arbitrarily 
chosen because of the logistics involved in trans- 
porting the patient to the cardiac catheterization 
laboratory. Later evaluation will result in higher 
patency rates because of continued thrombolysis. 
Fifth, the hydrostatic force of injecting contrast 
in the coronary artery can result in occasional 
patency. The TAM1 trials use the fourth angio- 
graphic injection as the endpoint rather than the 
first injection, increasing patency rates by ap- 
proximately 5%. Finally, studies with fewer than 
50 patients should not be given equal weight to 
studies with 100-200 patients. 
A recent review’ only analyzed studies using 
standard dosing (alteplase, 100 mg/3 hrs; APSAC, 
30 units/5 min; duteplase, 0.6 MU/4 hrs; saru- 
plase, 80 mg/l hr; streptokinase, 1.5 million units/ 
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1 hr), angiography, 90-minute patency, and mean 
symptom duration 2.5 to 4 hours. Whereas strep- 
tokinase had the lowest 90-minute patency rate 
(53%); alteplase, anistreplase, duteplase, and sar- 
uplase were equivalent (68’%, 7296, 6996, and 
72%, respectively). Note that the alteplase pat- 
ency rate with conventional dosing is lower than 
generally appreciated and no different from the 
duteplase result, as emphasized by the ISIS-3 in- 
vestigators. Previous reviews quoting higher pat- 
ency rates for alteplase were biased by including 
studies that used weight adjusted dosing sched- 
ules where more than 1 mg/kg of alteplase was 
given by 90 minutes. On the other hand, only 70 
mg of the 100 mg conventional dose is infused by 
the time of the 90-minute angiogram. When the 
full thrombolytic dose is given before the 90-min- 
Ute angiogram (front-loaded alteplase), as it is 
with the other thrombolytic agents, an 85% pat- 
ency rate is obtained. the highest rate yet re- 
ported for thrombolytic monotherapy. Patency 
rates are higher with combination thrombolytic 
therapy (alteplase/streptokinase, alteplasehroki- 
nase) than conventional dose monotherapy, but 
not as high as with front-loaded tPA therapy. By 
24 hours, equivalent patency rates of 85%-90% 
have been documented for all agents. 
Sherry and Marder’ have argued that all throm- 
bolytic agents are equally effective. In the early 
hours of myocardial infarction, when myocar- 
dium at risk can potentially be salvaged, they sug- 
gest that the agents can dissolve fresh fibrin 
equally well and achieve equivalent patency 
rates. As fibrin ages, it becomes more resistant 
to dissolution. Higher acute patency will be 
achieved with tPA relative to streptokinase be- 
cause of fibrin specificity, but significant salvage 
is no longer possible within this time frame. 
Therefore, equivalent results between agents 
with respect to left ventricular ejection fraction 
and mortality would again be expected from the 
open artery hypothesis because sustained pat- 
ency rates are equivalent several hours after 
treatment. 
However, it has yet to be proven that patency 
rates are equivalent among the agents in the first 
few hours of myocardial infarction. Moreover. 
when studies with similar methodologies are eval- 
uated. equivalent patency rates have not been 
achieved 3 hours after initiating therapy, as sug- 
gested by Sherry and Marde?; tPA rates are still 
5- 15 percentage points higher.’ 
Spontaneous patency develops in one third of 
patients during the first day of myocardial infarc- 
tion when thrornbolytic agents are not used and 
two thirds of infarct arteries ultimately become 
patent. The acute benefit has not been carefully 
evaluated, but later prognostic advantage has 
been claimed for spontaneous patency .9*10 
Before final patency status is determined, 
thrombus dissolution and reformation can occur 
several times. Higher fibrinogen levels may con- 
tribute to rethrombosis; lower fibrinogen levels 
and the resulting increase in the products of fi- 
brinogen degradation that exert potent antiplate- 
let and anticoagulant effects may favor continued 
patency. In support of this concept is the sugges- 
tion that patients treated with tPA have a higher 
incidence of recukent temporary thrombosis as 
measured by the continuous 12-lead ST segment 
monitor, compared with streptokinase.’I If fur- 
ther cellular damage is caused by recurrent occlu- 
sion, this could explain why no difference in left 
ventricular function or mortality has been shown 
to date in clinical trials despite differences in 
early patency rates between the agents. 
Therapeutic anticoagulation appears to be criti- 
cally important in maintaining patency achieved 
with alteplase. Patency rates > 90% were 
achieved angiographically when the activated 
partial thromboplastin time (aFTT) was consis- 
tently maintained over 2.0 times baseline in the 
ECSG-6I2 and HART’3 trials. Rates were more 
than 20 points lower when at least one aPTT mea- 
surement was < 60 seconds. In contrast, no sig- 
nificant patency advantage was found when intra- 
venous heparin was added to APSAC therapy.I4 
Angiographic reocclusion of the infarct artery 
doubles hospital mortality. I s  Half of these events 
occur in the first 24 hours and half of the 7-day 
reocclusion events are silent. In the absence of 
intravenous heparin adjunctive therapy, reocclu- 
sion rates of 20%-30% occur following alteplase 
therapy.I6.’’ Reocclusion rates associated with 
subcutaneous heparin adjunctive therapy are not 
known. Seven-day reocclusion rates of 10%-15% 
occur when aspirin and intravenous heparin are 
given with alteplase and fall below 10% with com- 
bination thrombolytic therapy and intravenous 
heparin.’ Seven-day reocclusion rates for strep- 
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tokinase and APSAC have not been well defined. 
The impact of more powerful antiplatelet therapy 
(monoclonal antibodies) and anticoagulant ther- 
apy (hirudin) on reocclusion rates are being stud- 
ied by the TAM1 and TIMI groups. 
Reperfusion momentum overcomes the ten- 
dency for reocclusion in the first 24 hours be- 
cause 24-hour patency rates are higher than 90- 
minute patency rates. However, patency rates 
decrease by approximately 10% from 24 hours to 
7 days.8 Interestingly, it appears that late reocclu- 
sion occurs in another 20% of patients by 3 
months.l8 These events may not carry the same 
clinical risk as early reocclusion. Perhaps collat- 
eral circulation formation makes many of these 
events clinically silent or they are associated with 
completed infarcts. 
It seems premature to conclude that all throm- 
bolytic drugs are equivalent and that further 
mechanistic evaluations are redundant . 3 , 1 9  
Rather, it may be that we are finally knowledg- 
able enough to ask the most important questions 
and design the appropriate studies to answer 
them. The GUSTO trial, for instance, will at- 
tempt to determine whether earlier or more sus- 
tained infarct artery patency can improve clinical 
outcome compared with intravenous streptoki- 
nase and subcutaneous heparin by studying intra- 
venous streptokinase and intravenous heparin; 
weight adjusted, front-loaded tPA, and intrave- 
nous heparin; and the combination of tPA and 
streptokinase plus intravenous heparin. Ninety- 
minute, 180-minute, and 24-hour patency rates 
will be determined to accurately define acute pat- 
ency rates in a randomized trial format with cur- 
rently available therapy and correlate them with 
clinical outcome. Moreover, by defining 7-day 
patency rates, reocclusion rates can be fairly 
compared. 
Besides investigating strategies to open the in- 
farct artery earlier or keep it open for 7 days, it 
will be important to see whether interventions 
that potentially reduce the number or duration of 
intermittent reocclusions (“cyclic flow varia- 
tions” in the animal literaturez0) in the early 
hours after thrombolysis, such as intravenous 
heparin (GUSTO), combination thrombolytic 
therapy (GUSTO, TIMI-4), antiplatelet mono- 
clonal antibodies (TAMI-8), or hirudin (TIMI-5, 
TIMI-6) improve left ventricular function. If 
there is a positive impact, we may ultimately be 
able to validate our initial paradigm, which sug- 
gested that acute patency preserves left ventricu- 
lar function and reduces morbidity and mortality. 
Then we could justify scientifically and economi- 
cally the intense efforts currently in progress to 
improve antiplatelet, anticoagulant, and throm- 
bolytic strategies and to decrease time to treat- 
ment in patients with acute myocardial infarction. 
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